BiotechTube

DYNE-101 + Placebo

Phase 1/2Recruiting
0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Myotonic Dystrophy Type 1 (DM1)

Conditions

Myotonic Dystrophy Type 1 (DM1)

Trial Timeline

Sep 5, 2022 → Jul 1, 2029

NCT ID
NCT05481879

About DYNE-101 + Placebo

DYNE-101 + Placebo is a phase 1/2 stage product being developed by Dyne Therapeutics for Myotonic Dystrophy Type 1 (DM1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05481879. Target conditions include Myotonic Dystrophy Type 1 (DM1).

What happened to similar drugs?

0 of 2 similar drugs in Myotonic Dystrophy Type 1 (DM1) were approved

Approved (0) Terminated (0) Active (2)
🔄Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
🔄DYNE-101 + PlaceboDyne TherapeuticsPhase 3

Hype Score Breakdown

Clinical
9
Activity
15
Company
9
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT07486934Phase 3Recruiting
NCT05481879Phase 1/2Recruiting

Competing Products

16 competing products in Myotonic Dystrophy Type 1 (DM1)

See all competitors
ProductCompanyStageHype Score
TideglusibAMO PharmaPre-clinical
20
TideglusibAMO PharmaPhase 2
25
Tideglusib + PlaceboAMO PharmaPhase 2/3
28
TideglusibAMO PharmaPhase 2/3
35
VX-670Vertex PharmaceuticalsPhase 2
42
VX-670 + PlaceboVertex PharmaceuticalsPhase 1/2
39
SAR446268SanofiPhase 1/2
39
rhIGF-I/rhIGFBP-3 + placeboInsmedPhase 2
32
IONIS-DMPKRx + PlaceboIonis PharmaceuticalsPhase 1/2
29
Del-desiran (AOC 1001)Avidity BiosciencesPhase 3
44
ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) InjectionArrowhead PharmaceuticalsPhase 1/2
36
DYNE-101 + PlaceboDyne TherapeuticsPhase 3
41
Pitolisant Oral Tablet + Placebo oral tabletHarmony BiosciencesPhase 2
29
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1PepGenPhase 2
32
PGN-EDODM1 for infusionPepGenPhase 1
19